Immuron Ltd — Regulatory Filings 2016

Nov 28, 2016

==> picture [213 x 60] intentionally omitted <==

Immuron Receives $1.6M R&D Tax Concession Refund

29 November 2016, Melbourne, Australia: Immuron Limited (ASX:IMC) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of $1.6 million for eligible research and development expenditure incurred during the 2016 Financial Year.

This refund reflects the Company’s $3.6M investment in research and development expenditure during the 2016 Financial Year toward the development of the Company’s pipeline programs including IMM-124E in NASH and ASH, IMM-529 in C. difficile, as well as the continuous development of the Company’s existing Travelan/Protectyn programs.

Immuron CEO Mr Thomas Liquard commented:

“We are grateful that the Australian Government is such a strong supporter of the development of early-stage biotechnology companies through the R&D Tax Concession initiative scheme. This cash refund scheme has allowed Immuron the opportunity to accelerate the clinical development timelines for a number of its high-value pipeline programs.”

The Company anticipates that its ongoing research and development programs, including components of its fatty-liver disease programs, will continue to be eligible for the Research and Development Income Tax Concession refund incentive program for the 2017 financial year.

- END –

Immuron Media Relations:

Company Contact: Immuron Media Relations: Thomas Liquard John Beveridge Chief Executive Officer Monsoon Communications Ph: +61 (0)3 9824 5254 Ph: +61 (0)3 9620 3333 thomasliquard@immuron.com johnb@monsoon.com.au

About Immuron:

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information, visit: http://www.immuron.com/

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

ABN: 80 063 114 045